Management of Hypertension with Female Sexual Dysfunction.
Zhong. Qing Q; Anderson. Yuri Y
Key Findings
- FSD is more common in hypertensive women than in normotensive women
- Beta‑blockers are linked to worse female sexual function, whereas ARBs may be beneficial
- Bremelanotide (pt‑141) can be considered for pre‑menopausal women with FSD alongside blood‑pressure control
Practical Outcomes
- If you’re hypertensive and care about sexual health, choose an ARB over a beta‑blocker when possible. Bremelanotide (pt‑141) can be tried as a short‑term peptide for pre‑menopausal FSD, but you’ll need a prescription and proper dosing. Keep blood pressure and overall health under regular monitoring while using any of these agents.
Summary
Women with high blood pressure often have more sexual problems. Some blood pressure medicines like beta‑blockers can worsen them, while ARBs may improve sexual function. For pre‑menopausal women, the peptide bremelanotide (pt‑141) and flibanserin are options; for post‑menopausal women, hormone‑based drugs are preferred.
Abstract
Female sexual dysfunction (FSD) in hypertension has been less studied than male sexual dysfunction, and antihypertensive agents' impact on female sexual function is not defined. In this review, randomized double-blind clinical trials and cross-sectional studies related to female sexual function in hypertension were analyzed from 1991 to 2021. FSD appeared to be higher in hypertensive women than in normotensive women. Beta-blockers are the only antihypertensive agents with relatively strong evidence of damaging the female sexual function. Angiotensin receptor blockers (ARB) are relatively beneficial to female sexual function. To treat FSD in the presence of hypertension, controlling blood pressure is key, and the administration of angiotensin receptor blockers is preferred. In addition to controlling blood pressure, for premenopausal women, flibanserin and bremelanotide can be tried, while ospemifene and hormone supplements are preferred for postmenopausal women.
Study Information
pubmed
2022
2022-05-05T00:00:00.000Z
10.3390/medicina58050637
11
43